Evaluation of an enoxaparin dosing calculator using burn size and weight

Journal of Burn Care and Research

Volumn 34, Issue 6, 2013, Pages 621-627

  Faraklas, Iris ^a   Ghanem, Maureen ^a   Brown, Amalia ^a   Cochran, Amalia ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN;

ADULT; ALCOHOL WITHDRAWAL; ALGORITHM; ANTICOAGULANT THERAPY; ARTICLE; BODY MASS; BODY WEIGHT; BURN; BURN SIZE; COMORBIDITY; CORRELATION ANALYSIS; CUTANEOUS PARAMETERS; DISEASE SEVERITY; DOSE CALCULATION; DRUG COST; DRUG DOSE CALCULATOR; DRUG SENSITIVITY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBESITY; RETROSPECTIVE STUDY; SEX DIFFERENCE; THERMAL INJURY; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ADULT; ALGORITHMS; ANTICOAGULANTS; BURN UNITS; BURNS; ENOXAPARIN; FEMALE; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84892781062     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/BCR.0b013e3182a2a855     Document Type: Article

References (26)

1. Cook D, Crowther M, Meade M, et al. Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med 2005;33:1565-71.
2. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 suppl):7S-47S.
3. Geerts WH, Bergqvist D, Pineo GF, et al.; American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 suppl):381S-453S.
4. Rue LW 3rd, Cioffi WG Jr, Rush R, McManus WF, Pruitt BA Jr. Thromboembolic complications in thermally injured patients. World J Surg 1992;16:1151-4; discussion 1155.
5. Wahl WL, Brandt MM, Ahrns KS, et al. Venous thrombosis incidence in burn patients: preliminary results of a prospective study. J Burn Care Rehabil 2002;23:97-102.
6. Ferguson RE, Critchfield A, Leclaire A, Ajkay N, Vasconez HC. Current practice of thromboprophylaxis in the burn population: a survey study of 84 US burn centers. Burns 2005;31:964-6.
7. Faucher LD, Conlon KM. Practice guidelines for deep venous thrombosis prophylaxis in burns. J Burn Care Res 2007;28:661-3.
8. Lin H, Faraklas I, Saffle J, Cochran A. Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients. J Trauma 2011;71:1557-61.
9. Rondina MT, Wheeler M, Rodgers GM, Draper L, Pendleton RC. Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients. Thromb Res 2010;125:220-3.
10. Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M. The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost 1989;62:940-4.
11. Costantini TW, Min E, Box K, et al. Dose adjusting enoxaparin is necessary to achieve adequate venous thromboembolism prophylaxis in trauma patients. J Trauma Acute Care Surg 2013;74:128-33; discussion 134-5.
12. Malinoski D, Jafari F, Ewing T, et al. Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients. J Trauma 2010;68:874-80.
13. Van PY, Cho SD, Underwood SJ, Morris MS, Watters JM, Schreiber MA. Thrombelastography versus AntiFactor Xa levels in the assessment of prophylactic-dose enoxaparin in critically ill patients. J Trauma 2009;66:1509-15; discussion 1515-7.
14. Lin H, Faraklas I, Cochran A, Saffle J. Enoxaparin and antifactor Xa levels in acute burn patients. J Burn Care Res 2011;32:1-5.
15. Yogaratnam D, Smith BS, Angood PB, Gandhi PJ. Antifactor Xa levels in four patients with burn injuries who received enoxaparin to prevent venous thromboembolism. Pharmacotherapy 2004;24:1793-9.
16. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A prospective study of venous thromboembolism after major trauma. N Engl J Med 1994;331:1601-6.
17. Fecher AM, O'Mara MS, Goldfarb IW, et al. Analysis of deep vein thrombosis in burn patients. Burns 2004;30:591-3.
18. Scholten DJ, Hoedema RM, Scholten SE. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg 2002;12:19-24.
19. Amin AN, Girard F, Samama MM. Does ambulation modify venous thromboembolism risk in acutely ill medical patients? Thromb Haemost 2010;104:955-61.
20. Harrington DT, Mozingo DW, Cancio L, Bird P, Jordan B, Goodwin CW. Thermally injured patients are at significant risk for thromboembolic complications. J Trauma 2001;50:495-9.
21. Pannucci CJ, Osborne NH, Wahl WL. Creation and validation of a simple venous thromboembolism risk scoring tool for thermally injured patients: analysis of the National Burn Repository. J Burn Care Res 2012;33:20-5.
22. Priglinger U, Delle Karth G, Geppert A, et al. Prophylactic anticoagulation with enoxaparin: is the subcutaneous route appropriate in the critically ill? Crit Care Med 2003;31:1405-9.
23. Dörffler-Melly J, de Jonge E, Pont AC, et al. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet 2002;359:849-50.
24. Bonate PL. Pathophysiology and pharmacokinetics following burn injury. Clin Pharmacokinet 1990;18:118-30.
25. Jaehde U, Sörgel F. Clinical pharmacokinetics in patients with burns. Clin Pharmacokinet 1995;29:15-28.
26. Haas CE, Nelsen JL, Raghavendran K, et al. Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients. J Trauma 2005;59:1336-43; discussion 1343-4.